Skip to content

Neuromuscular Electrical Stimulation (NMES) for Improving Outcomes Following Total Knee Arthroplasty (TKA)

Prospective Evaluation of Neuromuscular Electrical Stimulation (NMES) for Improving Outcomes Following Total Knee Arthroplasty (TKA)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03044028
Enrollment
66
Registered
2017-02-06
Start date
2017-01-31
Completion date
2018-08-31
Last updated
2020-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthropathy of Knee Joint

Brief summary

The current standard for rehabilitation after TKA consists of guided exercise therapy for up to 12 weeks after surgery. This includes inpatient, home, and outpatient therapy. The surgery and rehabilitation are highly successful at reducing or eliminating pain experienced preoperatively. However, quadriceps femoris muscle (QFM) strength, overall function, and knee range of motion are often worse than preoperative levels for as long as 6 months after surgery and in some cases may persist for many years after that. Such quadriceps strength impairments after TKA have been largely attributed to voluntary activation deficits and can lead to a decrease in functional performance such as decreased gait speed, decreased balance which can lead to falls, and decreased stair climbing & chair rise abilities. Since therapy alone does not adequately restore or improve upon the preoperative functional capabilities in a consistent and timely manner, it has been suggested that NMES used adjunctively with postoperative rehabilitation will alleviate the quadriceps muscle activation deficits. Early NMES use after TKA has been shown to: reduce knee extensor lag, increase walking speed, and improve QFM strength, knee range of motion, and function. However, NMES initiated one month after TKA did not lead to improved QFM strength or function beyond the standard benefits gained from exercise alone, thus suggesting that the timing of NMES application after TKA is important. It has previously been shown that preoperative QFM strength is predictive of postoperative function \[6\] but the benefit of prehabilitation remains in question. To date, there has only been one pilot study assessing the benefits of NMES when initiated preoperatively. This study only included 14 patients (9 NMES, 5 control) but was able to show that preoperative NMES usage may lead to greater QFM strength gains after TKA. Therefore, it will be important to assess the benefits of NMES both preoperatively and postoperatively in order to determine how it will be most beneficial to TKA patients.

Detailed description

The study duration will be until 12 weeks ± 1 week postoperatively. Data will be collected (1) 4 weeks preoperatively, (2) prior to hospital admission for TKA, and (3) at 3, 6, and 12 weeks postoperatively. The research coordinator at the site will identify, recruit, and prospectively follow the 66 patients at his/her site. All data will be entered and maintained in REDCap, an electronic data capture tools hosted at Cleveland Clinic. REDCap (Research Electronic Data Capture) is a secure, web-based application designed to support data capture for research studies, providing 1) an intuitive interface for validated data entry; 2) audit trails for tracking data manipulation and export procedures; 3) automated export procedures for seamless data downloads to common statistical packages; and 4) procedures for importing data from external sources. Only members of the study team (i.e. the personnel listed on the institutional review board (IRB) application) will have access to protected health information of patients included in this study. Pretreatment Assessments Before treatment, the following assessments/tests will be performed and the results will be recorded on the appropriate pages of the (case report form) CRF, and or Microsoft excel, Microsoft Word, and REDCap: * Informed consent * Age, gender, height/weight/(body mass index) BMI * Concomitant diseases * Physical examination * Baseline range of motion of affected knee * Baseline timed up and go test (TUG test, detailed in Appendix A and as described by Podsiadlo et al.) * Baseline Stair Climb test * Baseline QFM strength * Baseline Modified Knee Injury and Osteoarthritis Outcome Score (KOOS) and Veterans Rand 12(VR-12) assessments * Baseline VAS (visual analog scale)pain score * Current medications * Any use of ambulation assist device Presurgery Assessments Before surgery, the following assessments/tests will be performed and the results will be recorded on the appropriate pages of the CRF, and or Microsoft excel, Microsoft Word, and REDCap: * Device usage patterns (thru app for preop NMES group) * Range of motion of affected knee * TUG test * Stair Climb test * QFM strength * Modified KOOS and VR-12 assessments * VAS pain score * Current medications * Activity levels using Misfit Wearables® fitness monitor will be uploaded and incorporated into online app Operative Assessments The following will be collected from the Operative and Anesthesia Records and recorded on the appropriate pages of the CRF, and or Microsoft excel, Microsoft Word, and REDCap: * Surgeon name * Approach used * Randomization assignment * Diagnosis * Length of surgery * Estimated blood loss * Type of anesthesia * Implant type Postoperative Assessments After surgery, one or more of the following will be collected through the online app and at follow-up visits. * Device usage patterns (thru app) * Range of motion of affected knee (thru app and at follow-up) * TUG test * Stair Climb test * QFM strength * Modified KOOS and VR-12 assessments * VAS pain score * Length of stay (hospital, extended care facility) * 90 day readmission rate * Discharge Disposition (home vs skilled nursing facility vs inpatient rehabilitation) * Patient Satisfaction measures * Any use of an ambulation assist aid * Activity levels using Misfit Wearables® fitness monitor will be uploaded and incorporated into online app As a last resort, if a patient is unable to keep one of these appointments, he/she will be either be mailed or emailed the patient reported outcome forms so the patient can fill them out. The patient will date and time the forms. Participants will then send the form back in a pre-addressed envelope. The patients email will be verified by the patient during a clinical visit to ensure accuracy of the correct recipient. Patients not responding to the initial mailer will be contacted by phone and forms may be administered over the phone. The mailers and/or phone calls will allow us to collect all data except the physical function measures. All data will be entered and maintained in Redcap

Interventions

DEVICECyMedica Orthopedics QB1 e-vive™ system

a multifunctional electrotherapy device providing neuromuscular electrical stimulation (NMES), for improving quadriceps strength and improving functional outcomes accelerating functional recovery in patients managed with total knee arthroplasty (TKA).

Sponsors

The Cleveland Clinic
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

1. Patients undergoing unilateral primary total knee arthroplasty 2. Patients who are between the ages of 18 - 85 years 3. Patient has signed informed consent 4. Patient has access to a smartphone or tablet (Android or iOS)

Exclusion criteria

1. BMI ≥ 40 2. Inflammatory arthritis 3. Patients who are expected to be in extended care facilities after surgery 4. Patients who have used an at-home NMES device in the past 5. Preoperative daily use of narcotics (i.e., high tolerance) 6. Already enrolled in another research study, including the present study for contralateral knee 7. Other lower-extremity orthopaedic conditions which could interfere with limb function, especially those with significant pain requiring daily analgesic intake 8. Patients with concurrent abdominal, inguinal or femoral hernias 9. Cutaneous lesions in areas of electrode pad placement 10. Patients with a history of epilepsy 11. Patients with a cardiac pacemaker/defibrillator 12. Allergy to adhesives 13. Inability to meet follow-up visits required for the study 14. Patients who are a risk for poor compliance or have a poor understanding of the use of the NMES device 15. Condition deemed by physician or medical staff to be non-conducive to patient's ability to complete the study, or a potential risk to the patient's health and well-being

Design outcomes

Primary

MeasureTime frameDescription
Quadriceps Femoris Muscle (QFM) Strength (Dynamometer Quad Strength Lbs)6 weeksmeasure change in muscle strength (QFM) - difference from baseline measure to 6 weeks postoperative

Secondary

MeasureTime frameDescription
Visual Analogue Scale (VAS) Pain Level (0-10 Scale)12 weeksDifferences in VAS scores between the treatment groups from baseline to 12 weeks postop. Higher score represents worse pain.
Hospital Length of Stay (Days)12 weeksdifferences in length of stay between the treatment groups
Number of Patients Discharged to Extended Care Facility12 weeksPatent discharge other than home to extended care facility
Knee Active Range of Motion (Extension, Flexion) in Degrees12 weeksMeasure rage of motion differences between the treatment groups
Number of Outpatient Therapy Visits (Patient Questionnaire)12 weeksDifference in number of outpatient therapy visits among the treatment groups
KOOS - PS12 weeksFunctional outcomes using the Knee Injury and Osteoarthritis Outcome Score (KOOS) Physical Function Shortform (PS) questionnaire. Change in total score from baseline to 12 weeks postoperative score. Minimum value is 0, maximum value is 100, and higher values mean greater improvement over baseline total score.
KOOS Pain12 weeksMeasure pain at 12 weeks postoperative using Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain subscore. Change in total score from baseline to 12 weeks postoperative score. Minimum value is 0, maximum value is 100, and higher values mean greater improvement over baseline total score.
Number of Patients Readmitted to Hospital12 weeksNumber of all-cause readmissions to the hospital

Countries

United States

Participant flow

Participants by arm

ArmCount
NMES Preoperative and Postoperative
Subject will be given NMES CyMedica Orthopedics QB1 e-vive™ system device to use preoperative and will continue to use postoperatively until end of study CyMedica Orthopedics QB1 e-vive™ system: a multifunctional electrotherapy device providing neuromuscular electrical stimulation (NMES), for improving quadriceps strength and improving functional outcomes accelerating functional recovery in patients managed with total knee arthroplasty (TKA).
12
NMES Postoperative Only
Subject will be given NMES CyMedica Orthopedics QB1 e-vive™ system device to use postoperatively and will continue to use until end of study CyMedica Orthopedics QB1 e-vive™ system: a multifunctional electrotherapy device providing neuromuscular electrical stimulation (NMES), for improving quadriceps strength and improving functional outcomes accelerating functional recovery in patients managed with total knee arthroplasty (TKA).
12
No Intervention
Subject will not be given device and will undergo the standard rehab protocol alone
22
Total46

Baseline characteristics

CharacteristicNMES Postoperative OnlyNo InterventionTotalNMES Preoperative and Postoperative
Age, Continuous66.6 years
STANDARD_DEVIATION 6.3
64.5 years
STANDARD_DEVIATION 7.6
64.9 years
STANDARD_DEVIATION 6.7
64.0 years
STANDARD_DEVIATION 5.2
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
0 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
0 Participants
Region of Enrollment
United States
12 participants22 participants46 participants12 participants
Sex: Female, Male
Female
9 Participants17 Participants35 Participants9 Participants
Sex: Female, Male
Male
3 Participants5 Participants11 Participants3 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 220 / 220 / 22
other
Total, other adverse events
0 / 220 / 221 / 22
serious
Total, serious adverse events
0 / 220 / 220 / 22

Outcome results

Primary

Quadriceps Femoris Muscle (QFM) Strength (Dynamometer Quad Strength Lbs)

measure change in muscle strength (QFM) - difference from baseline measure to 6 weeks postoperative

Time frame: 6 weeks

Population: Numbers do not match Participant Flow because data were missing.

ArmMeasureValue (MEAN)Dispersion
NMES Preoperative and PostoperativeQuadriceps Femoris Muscle (QFM) Strength (Dynamometer Quad Strength Lbs)3.35 lbsStandard Deviation 20.7
NMES Postoperative OnlyQuadriceps Femoris Muscle (QFM) Strength (Dynamometer Quad Strength Lbs)15.95 lbsStandard Deviation 14.61
Control - no NMESQuadriceps Femoris Muscle (QFM) Strength (Dynamometer Quad Strength Lbs)-5.48 lbsStandard Deviation 16.53
Secondary

Hospital Length of Stay (Days)

differences in length of stay between the treatment groups

Time frame: 12 weeks

ArmMeasureValue (MEAN)Dispersion
NMES Preoperative and PostoperativeHospital Length of Stay (Days)1.83 daysStandard Deviation 0.72
NMES Postoperative OnlyHospital Length of Stay (Days)1.75 daysStandard Deviation 0.45
Control - no NMESHospital Length of Stay (Days)1.68 daysStandard Deviation 0.78
Secondary

Knee Active Range of Motion (Extension, Flexion) in Degrees

Measure rage of motion differences between the treatment groups

Time frame: 12 weeks

ArmMeasureValue (MEAN)Dispersion
NMES Preoperative and PostoperativeKnee Active Range of Motion (Extension, Flexion) in Degrees0.50 degreesStandard Deviation 13.22
NMES Postoperative OnlyKnee Active Range of Motion (Extension, Flexion) in Degrees6.67 degreesStandard Deviation 15.4
Control - no NMESKnee Active Range of Motion (Extension, Flexion) in Degrees-1.50 degreesStandard Deviation 12.93
Secondary

KOOS Pain

Measure pain at 12 weeks postoperative using Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain subscore. Change in total score from baseline to 12 weeks postoperative score. Minimum value is 0, maximum value is 100, and higher values mean greater improvement over baseline total score.

Time frame: 12 weeks

Population: Numbers do not match Participant Flow because data were missing.

ArmMeasureValue (MEAN)Dispersion
NMES Preoperative and PostoperativeKOOS Pain72.22 z-scoreStandard Deviation 19.64
NMES Postoperative OnlyKOOS Pain78.89 z-scoreStandard Deviation 16.57
Control - no NMESKOOS Pain80.38 z-scoreStandard Deviation 15.43
Secondary

KOOS - PS

Functional outcomes using the Knee Injury and Osteoarthritis Outcome Score (KOOS) Physical Function Shortform (PS) questionnaire. Change in total score from baseline to 12 weeks postoperative score. Minimum value is 0, maximum value is 100, and higher values mean greater improvement over baseline total score.

Time frame: 12 weeks

Population: Numbers do not match Participant Flow because data were missing.

ArmMeasureValue (MEAN)Dispersion
NMES Preoperative and PostoperativeKOOS - PS33.43 units on a scaleStandard Deviation 14.76
NMES Postoperative OnlyKOOS - PS20.39 units on a scaleStandard Deviation 12.7
Control - no NMESKOOS - PS26.62 units on a scaleStandard Deviation 9.81
Secondary

Number of Outpatient Therapy Visits (Patient Questionnaire)

Difference in number of outpatient therapy visits among the treatment groups

Time frame: 12 weeks

ArmMeasureValue (MEAN)Dispersion
NMES Preoperative and PostoperativeNumber of Outpatient Therapy Visits (Patient Questionnaire)12.86 visitsStandard Deviation 4.95
NMES Postoperative OnlyNumber of Outpatient Therapy Visits (Patient Questionnaire)16.25 visitsStandard Deviation 7.29
Control - no NMESNumber of Outpatient Therapy Visits (Patient Questionnaire)11.67 visitsStandard Deviation 5.06
Secondary

Number of Patients Discharged to Extended Care Facility

Patent discharge other than home to extended care facility

Time frame: 12 weeks

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
NMES Preoperative and PostoperativeNumber of Patients Discharged to Extended Care Facility0 Participants
NMES Postoperative OnlyNumber of Patients Discharged to Extended Care Facility0 Participants
Control - no NMESNumber of Patients Discharged to Extended Care Facility1 Participants
Secondary

Number of Patients Readmitted to Hospital

Number of all-cause readmissions to the hospital

Time frame: 12 weeks

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
NMES Preoperative and PostoperativeNumber of Patients Readmitted to Hospital0 Participants
NMES Postoperative OnlyNumber of Patients Readmitted to Hospital0 Participants
Control - no NMESNumber of Patients Readmitted to Hospital1 Participants
Secondary

Visual Analogue Scale (VAS) Pain Level (0-10 Scale)

Differences in VAS scores between the treatment groups from baseline to 12 weeks postop. Higher score represents worse pain.

Time frame: 12 weeks

Population: Numbers do not match Participant Flow because data were missing.

ArmMeasureValue (MEAN)Dispersion
NMES Preoperative and PostoperativeVisual Analogue Scale (VAS) Pain Level (0-10 Scale)2.00 units on a scaleStandard Deviation 2.92
NMES Postoperative OnlyVisual Analogue Scale (VAS) Pain Level (0-10 Scale)1.80 units on a scaleStandard Deviation 2.04
Control - no NMESVisual Analogue Scale (VAS) Pain Level (0-10 Scale)1.18 units on a scaleStandard Deviation 2.36

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026